Clinical Trials Logo

Hypochondroplasia clinical trials

View clinical trials related to Hypochondroplasia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06455059 Enrolling by invitation - Hypochondroplasia Clinical Trials

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

NCT ID: NCT06410976 Recruiting - Hypochondroplasia Clinical Trials

Prospective Clinical Assessment Study in Children With Hypochondroplasia

HCH
Start date: June 5, 2024
Phase:
Study type: Observational

This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).

NCT ID: NCT06212947 Recruiting - Hypochondroplasia Clinical Trials

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Start date: November 27, 2023
Phase:
Study type: Observational

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

NCT ID: NCT05328050 Recruiting - Achondroplasia Clinical Trials

Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)

OMPR-Ach/Hy
Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

This registry is a observational, single-center study designed to collect clinical data on patients with achondroplasia and hypochondroplasia.

NCT ID: NCT01541306 Completed - Achondroplasia Clinical Trials

C-Type Natriuretic Peptide and Achondroplasia

Start date: February 2012
Phase: N/A
Study type: Observational

Achondroplasia and hypochondroplasia are the most common forms of dwarfism. Recent studies have shown that a small hormone called C-type natriuretic peptide (CNP) is an important regulator of linear growth. The investigators believe that genetic abnormality that causes achondroplasia and hypochondroplasia also disrupts CNP signaling, which may contribute to the growth problem. The investigators propose to look at levels of this and other closely related hormones in children and adults with achondroplasia or hypochondroplasia to see if they are different from levels in healthy people. The investigators hypothesis is that CNP levels are elevated in children with achondroplasia or hypochondroplasia, compared the healthy population. Another hypothesis is that CNP levels are not elevated in adults with achondroplasia or hypochondroplasia, since adults have no growth-plate cartilage. By studying the potential role of the CNP system in achondroplasia and hypochondroplasia, not only will the investigators provide further insight into the pathophysiology of these common syndromes, the investigators will also provide greater insight into the regulation of normal linear growth.

NCT ID: NCT01111019 Completed - Hypochondroplasia Clinical Trials

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Start date: March 21, 2006
Phase: Phase 2
Study type: Interventional

This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.